Compare HWC & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HWC | BLLN |
|---|---|---|
| Founded | 1883 | 2016 |
| Country | United States | United States |
| Employees | 3658 | 713 |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.2B |
| IPO Year | N/A | N/A |
| Metric | HWC | BLLN |
|---|---|---|
| Price | $75.18 | $118.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $77.67 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 910.1K | 737.4K |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.59 | $46.29 |
| Revenue Next Year | $4.42 | $30.14 |
| P/E Ratio | $12.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.05 | $61.96 |
| 52 Week High | $76.39 | $138.70 |
| Indicator | HWC | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 68.19 | 62.10 |
| Support Level | $66.24 | $79.07 |
| Resistance Level | N/A | $138.70 |
| Average True Range (ATR) | 1.53 | 6.43 |
| MACD | 0.20 | 0.90 |
| Stochastic Oscillator | 87.79 | 76.08 |
Hancock Whitney Corp operates bank offices and financial centers. The company offers a range of traditional and online banking services to commercial, small business, and retail customers, providing a variety of transaction and savings deposit products, treasury management services, secured and unsecured loan products (including revolving credit facilities), letters of credit, and similar financial guarantees. The Bank provides trust and investment management services to retirement plans, corporations, and individuals and provides its customers access to investment advisory and brokerage products.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.